Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interaction between bone marrow stromal cells (BMSCs) and hematopoietic stem cells (HSCs) within the bone marrow niche is mediated significantly by Cadherin-2 (N-Cadherin) and Gap junction alpha-1 protein (Connexin 43) (Zhang et al., Nature, 2003; Cancelas et al., Blood, 2000). Cadherin-2 facilitates the physical anchoring of HSCs to the endosteal niche, which is crucial for maintaining stem cell quiescence and protecting them from environmental stressors (Hosokawa et al., Cell Stem Cell, 2010). Gap junction alpha-1 protein forms functional gap junctions that allow for direct metabolic and ionic signaling between the stromal microenvironment and hematopoietic cells, influencing cell cycle progression and survival (Taniguchi et al., Blood, 2012). In hematological malignancies, such as acute myeloid leukemia (AML), these interactions are often hijacked to protect leukemic stem cells from chemotherapy-induced apoptosis, contributing to drug resistance and relapse (Khoury et al., Leukemia, 2011). Therapeutic strategies targeting these molecules, such as the N-cadherin antagonist ADH-1 (Exherin) or Connexin 43 modulators like αCT1, aim to disrupt this protective niche and sensitize malignant cells to treatment (Perotti et al., J Clin Oncol, 2007; Grek et al., Cancers, 2014). However, because these proteins are widely expressed in other tissues—particularly Connexin 43 in the myocardium—systemic inhibition presents significant safety challenges, including potential cardiotoxicity (Smyth et al., J Clin Invest, 2010).
Disruption of N-cadherin-mediated adhesion and Connexin 43-mediated gap junctional communication between stromal cells and hematopoietic stem cells to sensitize malignant cells to therapy.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cadherin-2 (N-Cadherin) and Gap junction alpha-1 protein (Connexin 43) interaction (CDH2/GJA1).